UnknownPhase 2/3

Growth Hormone For Poor Ovarian Reserve Patients in ICSI Trials

Egypt120 participantsStarted 2022-02-01

Plain-language summary

Effect of Growth Hormone Adjuvant Therapy on ICSI Trials For Poor ovarian Reserve Patients

Age range20 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Advanced maternal age (40years).
✓. A previous poor ovarian response with 3 oocytes retrieved after conventional stimulation
✓. An abnormal ovarian reserve test (ORT)

✕. Any known contraindications to the approved fertility drugs.
✕. Any contraindications to growth hormone, pregnancy (to be ruled out and documented before GH treatment)

pregnancy rate

Timeframe: ICSI trial (1month)

NCT IDNCT05602090

SponsorBeni-Suef University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-09-04

Sara A Salem, MD